Uveal Melanoma
Conditions
Brief summary
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
Detailed description
The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
Interventions
None listed
Sponsors
Institut Curie
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Patients with metastatic uveal melanoma * Patients who received at least once injection of Nivolumab or Pembrolizumab in the case of the disease's treatment
Exclusion criteria
* Antecedent of another evolutionary tumor pathology
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response rate Data collection of the efficacity of PD-1 inhibitors | December 2019 | Description of Response rate |
| Progression Free Survival Data collection of the efficacity of PD-1 inhibitors | December 2019 | Description of PFS (Progression Free Survival) |
| Global Survival Data collection of the efficacity of PD-1 inhibitors | December 2019 | Description of Global Survival |
| Stability Data collection of the efficacity of PD-1 inhibitors | December 2019 | Description of Stability at 6 months |
| Objective response Data collection of the efficacity of PD-1 inhibitors | December 2019 | Description of Objective response |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Exploration of PD-1 inhibitors biomarkers | December 2019 | The study of PD-1 inhibitors biomarkers could be useful to identify a group of patients whose the molecules are most activated and then for futures studies. |
Countries
France
Outcome results
None listed